Goldline Pharmaceutical Ltd (544759) — Board Meeting | 29 August 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
AGM adopts FY2025-26 financials and declares dividend
🔄 What Changed
Revenue increased to ₹3,119.88 lakhs and profit to ₹411.71 lakhs
🔮 What's Next
Company will focus on expanding customer base, strengthening market presence, and pursuing sustainable growth in FY2026-27
💡 Investor Takeaway
Shareholders approved financials and dividend, signaling confidence in growth trajectory.

Goldline Pharmaceutical held its 22nd AGM on August 29, 2026 in Nagpur, adopting FY2025-26 financials with revenue rising to ₹3,119.88 lakhs and profit to ₹411.71 lakhs, declaring a ₹12 dividend per preference share, and reappointing Director Karkare, while highlighting post-listing growth plans and governance commitments.

📄 View Original Announcement (PDF)

About Goldline Pharmaceutical Ltd (544759)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹38.4 Cr

View full 544759 stock details →

📡 Get AI alerts when 544759 files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track 544759 — Free

📊 More 544759 filings

See all 544759 filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts for your stocks — summarized by AI daily

Set up your AI Radar — pick stocks, get daily email summaries of new filings.

Set up AI Radar — Free

Free account · 2 AI queries/day